EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

757 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-26

Study Completion Date

2017-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

NCT01756248

Macular Degeneration

COMPLETED

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

NCT02260687

Choroidal Neovascularization

COMPLETED

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

NCT02541084

Wet Macular Degeneration

COMPLETED

Eylea Post Marketing Surveillance(PMS)

NCT01783925

Macular Degeneration

COMPLETED

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

NCT02305238

Wet Macular Degeneration

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Intervention Type DRUG

Patients treated with EYLEA under practical manner for AMD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Patients treated with EYLEA under practical manner for AMD.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have been determined to start EYLEA treatment
* Patients who are registered to Special drug use investigation of EYLEA for AMD(Trial Number 15858)
* Patients who have agreed with the patient informed consent